Loading...
•
Dec 31, 2024
Zymeworks Q4 2024 Earnings Report
Zymeworks reported its fourth quarter 2024 financial results with increased revenue driven by milestone and royalty income but continued net loss.
Key Takeaways
For Q4 2024, Zymeworks generated revenue of 31000000 primarily due to initial royalty revenue and milestone payments from partnerships, while reporting a net loss of 23510000 and diluted EPS of -0.31 amid ongoing investment in pipeline development. Cash resources were 324200000 at quarter end. :contentReference[oaicite:0]{index=0}
Total revenue for Q4 2024 increased to 31000000 versus prior year, supported by royalty and milestone receipts. :contentReference[oaicite:1]{index=1}
Net loss was 23510000 with diluted EPS of -0.31. :contentReference[oaicite:2]{index=2}
Initial Ziihera product sales and royalties contributed to Q4 performance. :contentReference[oaicite:3]{index=3}
Cash resources remained strong at 324200000 at quarter end. :contentReference[oaicite:4]{index=4}
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company continues to invest in clinical pipeline and anticipates progression of key programs and potential additional milestones in 2025.
Positive Outlook
- FDA accelerated approval of Ziihera supports future royalty streams. :contentReference[oaicite:5]{index=5}
- Initial product royalties recognized in Q4 2024. :contentReference[oaicite:6]{index=6}
- Cash runway expected into second half of 2027. :contentReference[oaicite:7]{index=7}
- IND submission acceleration for ZW251 targeted mid-2025. :contentReference[oaicite:8]{index=8}
- First-in-human trials advancing for key pipeline assets. :contentReference[oaicite:9]{index=9}
Challenges Ahead
- Continued net loss and high operating expense levels. :contentReference[oaicite:10]{index=10}
- Dependency on milestones and royalties from partners. :contentReference[oaicite:11]{index=11}
- Cash resources declined year-over-year. :contentReference[oaicite:12]{index=12}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...